NC100692

structure in first source

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 08/01/2013 - "Blocking (99m)Tc-NC100692 uptake by pre-injecting the mice with excess unlabeled NC100692 reduced tumor uptake by approximately five-fold, to 0.68 ± 0.3% ID/g (p = 0.01). " 08/01/2013 - "The specificity of (99m)Tc-NC100692 was quantitatively evaluated in mice bearing subcutaneous U87MG tumors, by comparison of the biodistribution of (99m)Tc-NC100692 with that of the non-specific structural analogue (99m)Tc-AH-111744 and by blocking uptake of (99m)Tc-NC100692 with excess unlabeled NC100692. " 06/01/2007 - "NC100692 is under development as a diagnostic radiopharmaceutical for targeting angiogenesis associated with diseases, such as cancer and endometriosis. "
2.	Ischemia 06/21/2005 - "We evaluated a 99mTc-labeled peptide (NC100692) targeted at alpha(v)beta3 integrin for imaging in an established murine model of angiogenesis induced by hindlimb ischemia. "
3.	Inflammation (Inflammations) 12/01/2011 - "NC100692 imaging can detect vessel wall inflammation in vivo. "
4.	Endometriosis 06/01/2007 - "NC100692 is under development as a diagnostic radiopharmaceutical for targeting angiogenesis associated with diseases, such as cancer and endometriosis. "
5.	Breast Neoplasms (Breast Cancer) 07/01/2008 - "Integrin scintimammography with NC100692 and a dedicated gamma-camera, LumaGEM, based on semi-conductor technology, was performed to investigate the detection ability of this combination in breast cancer. "

1.	Gamma Cameras (Gamma Camera)